Autolus Therapeutics (AUTL) Operating Leases: 2018-2025
Historic Operating Leases for Autolus Therapeutics (AUTL) over the last 5 years, with Sep 2025 value amounting to $65.8 million.
- Autolus Therapeutics' Operating Leases rose 26.05% to $65.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.8 million, marking a year-over-year increase of 26.05%. This contributed to the annual value of $49.6 million for FY2024, which is 6.30% down from last year.
- Per Autolus Therapeutics' latest filing, its Operating Leases stood at $65.8 million for Q3 2025, which was up 2.01% from $64.5 million recorded in Q2 2025.
- In the past 5 years, Autolus Therapeutics' Operating Leases registered a high of $65.8 million during Q3 2025, and its lowest value of $11.3 million during Q3 2022.
- In the last 3 years, Autolus Therapeutics' Operating Leases had a median value of $51.3 million in 2024 and averaged $50.8 million.
- In the last 5 years, Autolus Therapeutics' Operating Leases tumbled by 61.23% in 2021 and then soared by 315.27% in 2023.
- Quarterly analysis of 5 years shows Autolus Therapeutics' Operating Leases stood at $21.0 million in 2021, then rose by 15.52% to $24.3 million in 2022, then skyrocketed by 118.37% to $53.0 million in 2023, then declined by 6.30% to $49.6 million in 2024, then climbed by 26.05% to $65.8 million in 2025.
- Its Operating Leases was $65.8 million in Q3 2025, compared to $64.5 million in Q2 2025 and $57.7 million in Q1 2025.